Dr. Heyman is a biopharmaceutical executive with over 25 years of experience in the industry. Most recently he served as CEO of Seragon Pharmaceuticals, a company focused on the development of drugs targeting hormone dependent cancers that was acquired by the Roche group. He was also co-founder and CEO of Aragon Pharmaceuticals, which was purchased by Johnson & Johnson in 2013. Previously, he co-founded and served as Chief Scientific Officer of X-Ceptor Therapeutics, a company that developed compounds targeting nuclear receptors for the treatment of metabolic diseases, acquired by Exelixis in 2004. As Vice President of Research at Ligand Pharmaceuticals, he led the development of Panretin® and Targretin®, retinoids approved by the FDA for the treatment of cancer. He is the author or inventor on more than 120 publications and patents. Dr. Heyman serves on the Board of Directors for BIOCOM, Organovo Inc., The Jenna Druck Center, and ORIC Pharmaceuticals. He was a NIH postdoctoral fellow at the Salk Institute and received a Ph.D. in pharmacology from the University of Minnesota. He completed his B.S. in chemistry from the University of Connecticut.